Schizophrenia remains a global problem creating a profound impact on individual and societal functioning. Common management strategies include a variety of options using oral and injectable antipsychotic drugs, psychotherapy, and strategies to assist the patient to reintegrate into society. Noncompliance with pharmacologic therapies is a very common issue that needs solutions. Professor Christoph Correll of the Department of Psychiatry, Zucker Hillside Hospital Glen Oaks, New York, US, shared his insights on current and novel treatment options for schizophrenia and the advantages of using atypical long-acting injectable (LAI) antipsychotics such as paliperidone palmitate.
Warfarin is effective in preventing stroke in patients with atrial fibrillation (AF), but the potential benefits are not always borne out in clinical practice as patients are often not adequately anticoagulated. Non-vitamin K antagonist oral anticoagulants (NOACs) are promising alternatives with proven efficacy and safety in stroke prevention in AF and are easier to administer. At a Daiichi Sankyo-sponsored symposium organized by the Hong Kong College of Cardiology, Professor Stuart Connolly of the McMaster University, Ontario, Canada, discussed the potential benefits of NOACs for AF patients. In particular, he highlighted the beneficial trade-off between stroke prevention and bleeding risk offered by the NOAC edoxaban (Lixiana™, Daiichi Sankyo) in elderly patients with AF, the patient population with the highest stroke risk.
As antiretroviral therapy (ART) for HIV continues to evolve, there is growing concern among patients and doctors regarding ART-associated toxicities. At a Janssen-sponsored symposium in Hong Kong, Professor Alan Winston of the St. Mary’s Hospital in London, UK, discussed some of these ART-associated toxicities and the benefits of strategies such as ART simplification to a single-tablet regimen of rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF), and the promising results of dual therapy with a boosted protease inhibitor (PI) darunavir (DRV) and lamivudine (3TC).
Prompt and effective treatment strategies for patients with chronic obstructive pulmonary disease (COPD) are crucial to improve outcomes. At the Autumn Respiratory Seminar 2016 in Hong Kong, Professor Andrew McIvor of the Firestone Institute for Respiratory Health, St. Joseph's Healthcare in Ontario, Canada, highlighted the importance of optimizing the use of a long-acting β2-agonist (LABA) with a long-acting muscarinic antagonist (LAMA), the continued role of LABA with inhaled corticosteroids (ICS) in preventing exacerbations, and the emerging role of the oral phosphodiesterase 4 (PDE4) inhibitor roflumilast in patients with COPD.
Patients with chronic obstructive pulmonary disease (COPD) commonly experience acute exacerbations, which are most commonly triggered by viruses. Prompt and effective treatment is required to reduce the rate of exacerbations and this affects disease progression. Studies showed that long-acting muscarinic antagonists (LAMAs) and/or long-acting β2-agonists (LABAs) are safer than inhaled corticosteroids (ICS) for long-term use. At the Autumn Respiratory Seminar 2016, Professor Wisia Wedzicha of Imperial College, London, UK, discussed the results of LABA/LAMA therapy trials and the efficacy of indacaterol in combination with glycopyrronium (Ultibro®, Novartis) in reducing COPD exacerbations.
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, was associated with a reduced rate of disability progression in individuals with primary progressive multiple sclerosis (MS), based on findings of the phase III ORATORIO* trial.
The management of osteoporosis calls for a range of strategies, including pharmacotherapy. At a meeting organized by The Osteoporosis Society of Hong Kong, Professor Markus Seibel of the University of Sydney, Australia, reviewed current pharmacological therapies for osteoporosis.